Another study revealed that supplementation with ω-3 PUFAs, along with lycopene and rosuvastatin, decreased plasma IL-6 levels and restored leukotriene B4 receptor gene expression to its initial levels in COPD patients [148]. Here, IL6 is linked to chronic obstructive pulmonary disease.